局部区域放疗联合化疗和免疫治疗新诊断转移性鼻咽癌的真实世界回顾性研究：来自两个癌症中心的数据。

Loco-regional radiotherapy in de novo metastatic nasopharyngeal carcinoma with chemotherapy and immunotherapy: A real-world retrospective study from two cancer centers.

机构信息

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital & Shenzhen Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Shenzhen, China.

National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

出版信息

Head Neck. 2024 Aug;46(8):1932-1937. doi: 10.1002/hed.27665. Epub 2024 Feb 5.

DOI:10.1002/hed.27665

PMID:38317293

Abstract

BACKGROUND

Immunochemotherapy has become the first-line treatment for initial diagnosed metastatic nasopharyngeal carcinoma (mNPC). Loco-regional radiotherapy combined with systemic chemotherapy significantly improves the survival. However, the safety and efficacy of loco-regional radiotherapy combined with immunochemotherapy remained unknown.

METHODS

Patients with de novo mNPC who received immunochemotherapy followed by loco-regional radiotherapy were included from two cancer centers. Toxicity and treatment response were assessed using CTCAE 5.0 and RECIST 1.1, respectively. Overall survival (OS) and progression-free survival (PFS) were analyzed using the Kaplan-Meier method.

RESULTS

From 2019 to 2021, a total of 16 patients were retrospectively analyzed. The median follow-up was 28 months (range 14-47 months). No one died. One-year, 2-year, and 3-year PFS rate was 93.8%, 58.4% and 50.1%, respectively. Radiotherapy-related acute severe (grade 3 or higher) toxicity was dermatitis (1/16, 6.3%) and mucositis (2/16, 12.5%).

CONCLUSIONS

Loco-regional radiotherapy provided a promising efficacy with modest toxicity for patients with mNPC who received immunochemotherapy.

摘要

背景

免疫化疗已成为初诊转移性鼻咽癌（mNPC）的一线治疗方法。局部区域放疗联合全身化疗显著提高了生存率。然而，局部区域放疗联合免疫化疗的安全性和疗效仍不清楚。

方法

从两个癌症中心纳入接受免疫化疗后行局部区域放疗的初诊 mNPC 患者。使用 CTCAE 5.0 和 RECIST 1.1 分别评估毒性和治疗反应。使用 Kaplan-Meier 法分析总生存期（OS）和无进展生存期（PFS）。

结果

2019 年至 2021 年，共回顾性分析了 16 例患者。中位随访时间为 28 个月（范围 14-47 个月）。无死亡病例。1 年、2 年和 3 年 PFS 率分别为 93.8%、58.4%和 50.1%。放疗相关急性重度（≥3 级）毒性为皮炎（1/16，6.3%）和黏膜炎（2/16，12.5%）。